🔗 Share this article

While the US proceeds with sweeping adjustments to its immunization recommendations, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning Covid shots throughout the global health crisis and has zeroed in on potential fatalities after COVID-19 immunization in her brief position at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Schedule

Agency leaders planned to reveal sweeping changes to the childhood vaccination calendar in December, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of alignment with much of the international standard with no evidence for public health gain. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is listed to address the audience at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this year.

A Shift at the Agency

This interim role may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a society with universal health coverage and a population about the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

Dr. Høeg has little discernible track record in drug development, approval processes or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “understand legal statutes and the science of medication creation”, said Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who led CBER have had.”

The drug center has an vast workload at the FDA, she stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these must be looked after,” she explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a major administrative component to the role, which oversees in excess of 5,000 staff members. “It is a huge leadership role, if you execute it properly,” she concluded.

Official Statement and Controversial Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “inquiries rely on flawed premises”.

“Her experience matches the duties of her position,” the spokesperson said, noting the period Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a contentious expedited therapy clearance system that allegedly concerned her predecessors. “How are these therapies being chosen for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of most medications, with the exception of shots.”

Public Past Work on Immunizations

With immunizations, Høeg has a more documented, if concerning, history, Howard have noted. She published a analysis using non-validated crowd-sourced reports to determine the frequency of myocarditis following COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are riskier than they are.

Among her “wish list” for the current administration featured revising rules for recently developed shots and halting “optional” vaccines, she said post-election on a podcast. At the FDA, Dr. Høeg has reportedly proposed preventing teenage boys from getting COVID-19 vaccines.

“She is an all-around dogmatist who commences with her conclusions and reverse-engineers to retrofit the science in a very deceptive, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|